Background: Estradiol at baseline or after a classical gonadotropin-releasing hormone test did not reflect ovarian steroidogenesis in central precocious puberty (CPP) girls. Aims: To evaluate estradiol response to depot triptorelin, both at start and during therapy to determine how active ovarian steroidogenesis is at pubertal stage and under therapy. Methods: A prospective study was performed in 43 CPP girls. Serum luteinizing hormone and follicle-stimulating hormone at 3 h (LH-3h, FSH-3h) and estradiol at 24 h (E2-24h) after injection of depot triptorelin 3.75 mg were measured, at first dose and at 3, 6, 12, 18 and 24 months of treatment. Results: E2-24h after depot triptorelin was >100 pg/ml after the first dose. Estradiol response (E2-24h) fell to levels <14 pg/ml in 78 out of 82 follow-up visits along 2 years of therapy. Concomitantly, LH-3h and FSH-3h were <4.0 and <6.3 IU/l, respectively. In 4 patients with inadequate treatment, E2-24h, LH-3h and FSH-3h rose to pubertal values similar to those observed at first dose. Conclusion: Estradiol (<14 pg/ml) assessment 24 h after depot triptorelin administration is a reliable and simple manner to confirm ovarian suppression in CPP girls during treatment.

Keywords:
Estradiol, Ovary, Luteinizing hormone, Gonadotropin-releasing hormone analogue, Precocious puberty
1.
Carel JC, Leger J: Clinical practice. Precocious puberty. N Engl J Med 2008;358:2366-2377.
2.
Bulcao MD, Nahime BV, Latronico AC: New causes of central precocious puberty: the role of genetic factors. Neuroendocrinology 2014;100:1-8.
3.
Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR, Antoniazzi F, Berenbaum S, Bourguignon JP, Chrousos GP, Coste J, Deal S, de VL, Foster C, Heger S, Holland J, Jahnukainen K, Juul A, Kaplowitz P, Lahlou N, Lee MM, Lee P, Merke DP, Neely EK, Oostdijk W, Phillip M, Rosenfield RL, Shulman D, Styne D, Tauber M, Wit JM: Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009;123:e752-e762.
4.
Lawson ML, Cohen N: A single sample subcutaneous luteinizing hormone (LH)-releasing hormone (LHRH) stimulation test for monitoring LH suppression in children with central precocious puberty receiving LHRH agonists. J Clin Endocrinol Metab 1999;84:4536-4540.
5.
Lee PA: Laboratory monitoring of children with precocious puberty. Arch Pediatr Adolesc Med 1994;148:369-376.
6.
Salerno M, Di Maio S, Gasparini N, Mariano A, Macchia V, Tenore A: Central precocious puberty: a single blood sample after gonadotropin-releasing hormone agonist administration in monitoring treatment. Horm Res 1998;50:205-211.
7.
Kunz GJ, Sherman TI, Klein KO: Luteinizing hormone (LH) and estradiol suppression and growth in girls with central precocious puberty: is more suppression better? Are pre-injection LH levels useful in monitoring treatment? J Pediatr Endocrinol Metab 2007;20:1189-1198.
8.
Lahlou N, Carel JC, Chaussain JL, Roger M: Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics. J Pediatr Endocrinol Metab 2000;13(suppl 1):723-737.
9.
Freire AV, Escobar ME, Gryngarten MG, Arcari AJ, Ballerini MG, Bergada I, Ropelato MG: High diagnostic accuracy of subcutaneous Triptorelin test compared with GnRH test for diagnosing central precocious puberty in girls. Clin Endocrinol (Oxf) 2013;78:398-404.
10.
Greulich WW, Pyle SI: Radiographic Atlas of Skeletal Development of the Hand and Wrist, ed 2. Stanford, Stanford University Press, 1959.
11.
Mason-Garcia M, Vigh S, Comaru-Schally AM, Redding TW, Somogyvari-Vigh A, Horvath J, Schally AV: Radioimmunoassay for 6-D-tryptophan analog of luteinizing hormone-releasing hormone: measurement of serum levels after administration of long-acting microcapsule formulations. Proc Natl Acad Sci USA 1985;82:1547-1551.
12.
Elsholz DD, Padmanabhan V, Rosenfield RL, Olton PR, Phillips DJ, Foster CM: GnRH agonist stimulation of the pituitary-gonadal axis in children: age and sex differences in circulating inhibin-B and activin-A. Hum Reprod 2004;19:2748-2758.
13.
Bhatia S, Neely EK, Wilson DM: Serum luteinizing hormone rises within minutes after depot leuprolide injection: implications for monitoring therapy. Pediatrics 2002;109:E30.
14.
Brito VN, Latronico AC, Arnhold IJ, Mendonca BB: A single luteinizing hormone determination 2 h after depot leuprolide is useful for therapy monitoring of gonadotropin-dependent precocious puberty in girls. J Clin Endocrinol Metab 2004;89:4338-4342.
15.
Demirbilek H, Alikasifoglu A, Gonc NE, Ozon A, Kandemir N: Assessment of gonadotrophin suppression in girls treated with GnRH analogue for central precocious puberty; validity of single luteinizing hormone measurement after leuprolide acetate injection. Clin Endocrinol (Oxf) 2012;76:126-130.
16.
Pescovitz OH, Comite F, Hench K, Barnes K, McNemar A, Foster C, Kenigsberg D, Loriaux DL, Cutler GB Jr: The NIH experience with precocious puberty: diagnostic subgroups and response to short-term luteinizing hormone releasing hormone analogue therapy. J Pediatr 1986;108:47-54.
17.
Lewis KA, Eugster EA: Random luteinizing hormone often remains pubertal in children treated with the histrelin implant for central precocious puberty. J Pediatr 2013;162:562-565.
18.
Neely EK, Silverman LA, Geffner ME, Danoff TM, Gould E, Thornton PS: Random unstimulated pediatric luteinizing hormone levels are not reliable in the assessment of pubertal suppression during histrelin implant therapy. Int J Pediatr Endocrinol 2013;2013:20.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.